Borgwarner Inc (BWA) 32.20 $BWA BorgWarner Falls 3.62%

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Borgwarner Inc (BWA) 32.20 $BWA

BorgWarner Falls 3.62% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Aug 02, 3:51PM CDT
BorgWarner (NYSE:BWA) traded in a range yesterday that spanned from a low of $31.49 to a high of $32.91. Yesterday, the shares fell 3.6%, which took the trading range below the 3-day low of $31.94 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BWA: 32.20 (+0.07)

BorgWarner Set to Possibly Rebound After Yesterday's Selloff of 3.62%
Comtex SmarTrend(R) - Tue Aug 02, 3:49PM CDT
BorgWarner (NYSE:BWA) traded in a range yesterday that spanned from a low of $31.49 to a high of $32.91. Yesterday, the shares fell 3.6%, which took the trading range below the 3-day low of $31.94 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BWA: 32.20 (+0.07)

BorgWarner (BWA) Beats on Q2 Earnings, Revises '16 View
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:34AM CDT
BorgWarner Inc. (BWA) reported adjusted earnings of 84 cents per share in the second quarter of 2016, higher than 75 cents recorded in the year-ago quarter.
BWA: 32.20 (+0.07), SPAR: 8.28 (-0.01), GNTX: 17.40 (+0.26), JCI: 45.00 (-0.23)

BorgWarner's (BWA) Q2 Earnings Beat Estimates, Rise Y/Y
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:30AM CDT
BorgWarner (BWA) reported adjusted earnings of 84 cents per share in the second quarter of 2016, beating the Zacks Consensus Estimate of 82 cents.
BWA: 32.20 (+0.07)

BorgWarner Reports Second Quarter 2016 U.S. GAAP Net Earnings Of $0.76 Per Diluted Share, Or $0.84 Per Diluted Share Excluding Non-Comparable Items
PR Newswire - Thu Jul 28, 7:00AM CDT
BorgWarner Inc. (NYSE: BWA) today reported second quarter results.
BWA: 32.20 (+0.07)

SmarTrend Watching for Potential Pullback in Shares of BorgWarner After 1.28% Gain
Comtex SmarTrend(R) - Wed Jul 27, 3:28PM CDT
BorgWarner (NYSE:BWA) traded in a range yesterday that spanned from a low of $33.81 to a high of $34.71. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $34.03 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BWA: 32.20 (+0.07)

Look for Shares of BorgWarner to Potentially Pullback after Yesterday's 1.28% Rise
Comtex SmarTrend(R) - Wed Jul 27, 3:26PM CDT
BorgWarner (NYSE:BWA) traded in a range yesterday that spanned from a low of $33.81 to a high of $34.71. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $34.03 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BWA: 32.20 (+0.07)

Auto Stocks' Q2 Earnings on Jul 28: F, HOG, LEA, BWA, CPS
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 7:26AM CDT
Let's see what awaits these five auto stocks slated to release their second-quarter 2016 results on Jul 28.
BWA: 32.20 (+0.07), HOG: 51.55 (+0.09), F: 12.06 (+0.12), CPS: 88.34 (+0.55), LEA: 109.28 (+0.17)

BorgWarner Provides On-Demand Transfer Case For Jaguar Land Rover Vehicles
PR Newswire - Thu Jul 07, 7:00AM CDT
BorgWarner delivers its innovative pre-emptive on-demand transfer case for multiple Jaguar models. Initially available for the new Jaguar XF, BorgWarner will also provide the all-wheel drive (AWD) technology for the Jaguar XE and F-PACE crossover. BorgWarner produces the AWD transfer case for the Jaguar XF at its newly built energy-efficient facility in Oroszlány, Hungary. Jaguar Land Rover is the first European automaker to feature BorgWarner's advanced AWD solution.
BWA: 32.20 (+0.07)

Downgrade Alert for BorgWarner (BWA)
Comtex SmarTrend(R) - Wed Jun 22, 3:21AM CDT
BorgWarner (NYSE:BWA) was downgraded from Buy to Neutral at BofA/Merrill today. The stock closed yesterday at $33.35 on volume of 3.2 million shares, above average daily volume of 2.1 million. BorgWarner, Inc. supplies engineered systems and components, primarily for automotive powertrain applications. The Company's products are manufactured and sold worldwide, primarily to original equipment manufacturers of passenger cars, sport utility vehicles, and light trucks. BorgWarner operates manufacturing facilities in North America, Europe, and Asia.
BWA: 32.20 (+0.07)

BorgWarner Chain Drive Systems Featured On Cummins® 5.0-liter V8 Diesel Engine
PR Newswire - Thu Jun 16, 7:00AM CDT
BorgWarner is expanding its engine timing systems and drive chains into the North American light-duty diesel market with the Cummins® 5.0-liter turbodiesel V8 engine family. Optimized specifically for Cummins V8 engines, BorgWarner's engine timing system includes bushing timing chains, arms, guides, tensioners and sprockets. BorgWarner also supplies chains for the fuel injection pump drive and oil pump drive, both designed for wear resistance and low noise.
BWA: 32.20 (+0.07)

Watch for BorgWarner to Potentially Rebound After Falling 2.38% Yesterday
Comtex SmarTrend(R) - Wed Jun 01, 2:46PM CDT
BorgWarner (NYSE:BWA) traded in a range yesterday that spanned from a low of $32.71 to a high of $33.85. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $33.07 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BWA: 32.20 (+0.07)

BorgWarner Falls 2.38% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Jun 01, 2:44PM CDT
BorgWarner (NYSE:BWA) traded in a range yesterday that spanned from a low of $32.71 to a high of $33.85. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $33.07 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BWA: 32.20 (+0.07)

What's in the Cards for Navistar (NAV) in Q2 Earnings? (revised)
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 1:36PM CDT
Navistar International Corporation (NAV) is set to report second-quarter fiscal 2016 (ended Apr 30, 2016) results on Jun 2.
BWA: 32.20 (+0.07), CMI: 121.89 (+0.85), ALV: 103.42 (+0.17), NAV: 11.91 (-0.03)

What's in the Cards for Navistar (NAV) in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 31, 7:09AM CDT
Navistar International Corporation (NAV) is set to report second-quarter fiscal 2016 (ended Apr 30, 2016) results on Jun 2.
BWA: 32.20 (+0.07), CMI: 121.89 (+0.85), ALV: 103.42 (+0.17), NAV: 11.91 (-0.03)

Borg-Warner Trophy(TM) Presented To Alexander Rossi, Winner Of The 100th Running Of The Indianapolis 500
PR Newswire - Mon May 30, 9:40AM CDT
Following the 100th running of the Indianapolis 500, BorgWarner President and Chief Executive Officer James R. Verrier presented the Borg-Warner Trophy(TM) to 2016 winner Alexander Rossi in Victory Lane. With the win, Rossi earned his place on the famous trophy, a sterling silver icon of racing history.
BWA: 32.20 (+0.07)

Belli, Melvin And Timmermans Win 2016 Louis Schwitzer Award
PR Newswire - Fri May 20, 7:54PM CDT
The 50th annual Louis Schwitzer Award has been presented to engineers Tino Belli from INDYCAR, Arron Melvin from Chevrolet, and Alex Timmermans from Dallara for the Rear Beam Wing Flap. The passive safety device normally remains flush with the beam wing of the race car. In the event of a spin, the Rear Beam Wing Flap deploys automatically to increase drag, slow the spin and prevent the car from becoming airborne. Once the airflow is normalized, spring-loaded hinges return the device to the flush position.
BWA: 32.20 (+0.07)

BorgWarner Expands North American REMAN Turbocharger Line
PR Newswire - Thu May 19, 9:00AM CDT
BorgWarner is expanding its successful North American REMAN turbocharger line to include turbochargers of all brands. REMAN--or remanufactured--turbochargers combine the quality of a new original turbocharger with the competitiveness of a remanufactured system. They are professionally restored with new production validated parts on BorgWarner series assembly lines to meet the same high-quality performance standards as new turbochargers. All BorgWarner REMAN turbochargers are backed by a 12-month unlimited mileage warranty.
BWA: 32.20 (+0.07)

BorgWarner Rises 1.20% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed May 11, 2:28PM CDT
BorgWarner (NYSE:BWA) traded in a range yesterday that spanned from a low of $33.91 to a high of $34.66. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $34.41 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BWA: 32.20 (+0.07)

After Yesterday's Rally of 1.20% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed May 11, 2:26PM CDT
BorgWarner (NYSE:BWA) traded in a range yesterday that spanned from a low of $33.91 to a high of $34.66. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $34.41 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BWA: 32.20 (+0.07)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 399

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 448

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 0

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 14

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

O-I Glass Announces Participation in Citi’s 2025 Conference

Updated Category News Views 208

O-I Glass Participation in the 2025 Basic Materials Conference PERRYSBURG, Ohio — O-I Glass, Inc., known for its commitment to creating exceptional glass products, is set to participate in the upcoming Citi’s 2025 Basic Materials Conference. This significant event will take place on a Wednesday in December, and features notable presentations from O-I's leadership....

Continue Reading
Osmium Partners Proposes Strategic Plan for Articore Growth

Updated Category News Views 104

Osmium Partners Proposes a Four-Step Plan for Articore Osmium Partners has recently made headlines with their proposal for Articore, aiming to elevate shareholder value through a methodical four-step approach. This initiative is driven by Osmium's belief that Articore's current management strategy lacks direction and has resulted in missed opportunities for growth and...

Continue Reading
Amplify Energy Set to Shine at EnerCom Denver Conference 2025

Updated Category News Views 135

Amplify Energy’s Participation in EnerCom Denver Conference Amplify Energy Corp. is gearing up to participate in the renowned annual EnerCom Denver Conference in 2025. This event, known for bringing together leading experts and investors in the energy sector, offers Amplify a prime platform to showcase its strategic initiatives and growth potential. Focus on Investor...

Continue Reading
Safe Life Expands CPR Training and AED Services through Acquisition

Updated Category News Views 197

Safe Life Strengthens National Coverage for Life-Saving Training Safe Life has made a significant move by acquiring HeartCert, a company known for its specialization in automated external defibrillators (AEDs) and CPR training. This acquisition allows Safe Life to broaden its reach into the Midwest, enhancing its commitment to providing life-saving training and equipment...

Continue Reading
Express Scripts Challenges FTC's Drug Pricing Conclusions

Updated Category News Views 106

Express Scripts Files Lawsuit Against the FTC Express Scripts, a major player in the pharmacy benefit manager sector, has recently taken legal action against the U.S. Federal Trade Commission (FTC). This lawsuit stems from a report that criticizes the role of pharmacy benefit managers in the pricing of medications. Express Scripts contends that the report's conclusions...

Continue Reading